Cargando...
Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience
Antibody-mediated rejection (AMR) is not uncommon after renal transplantation and is harder to handle compared to cell-mediated rejection. When refractory to conventional therapies, rituximab is an attractive option. This study aims to examine the effectiveness of rituximab in refractory late acute...
Gardado en:
| Publicado en: | Indian J Nephrol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5015507/ https://ncbi.nlm.nih.gov/pubmed/27795623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0971-4065.177207 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|